Dr Kim Moran-Jones
- Affiliate (MVLS College Services)
email:
Kim.Moran-Jones@glasgow.ac.uk
Usher Building, University of Edinburgh, EH16 4UX
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar and Clarity help us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Kim.Moran-Jones@glasgow.ac.uk
Usher Building, University of Edinburgh, EH16 4UX
Moser, R. et al. (2022) Pharmacological targeting of TFIIH suppresses KRAS mutant pancreatic ductal adenocarcinoma and synergizes with TRAIL. Cancer Research, 82(18), pp. 3375-3393. (doi: 10.1158/0008-5472.CAN-21-4222) (PMID:35819261)
Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)
Dreyer, S. B. et al. (2020) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, 272(2), pp. 366-376. (doi: 10.1097/SLA.0000000000003143) (PMID:32675551) (PMCID:PMC7373491)
Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)
Moran-Jones, K. (2016) The therapeutic potential of targeting the HGF/cMET axis in ovarian cancer. Molecular Diagnosis and Therapy, 20(3), pp. 199-212. (doi: 10.1007/s40291-016-0201-8) (PMID:27139908)
Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi: 10.1038/nature16965) (PMID:26909576)
Moran-Jones, K. et al. (2015) Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 6(42), pp. 44551-44562. (doi: 10.18632/oncotarget.6082) (PMID:26575166) (PMCID:PMC4792575)
Moser, R. et al. (2022) Pharmacological targeting of TFIIH suppresses KRAS mutant pancreatic ductal adenocarcinoma and synergizes with TRAIL. Cancer Research, 82(18), pp. 3375-3393. (doi: 10.1158/0008-5472.CAN-21-4222) (PMID:35819261)
Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)
Dreyer, S. B. et al. (2020) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, 272(2), pp. 366-376. (doi: 10.1097/SLA.0000000000003143) (PMID:32675551) (PMCID:PMC7373491)
Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)
Moran-Jones, K. (2016) The therapeutic potential of targeting the HGF/cMET axis in ovarian cancer. Molecular Diagnosis and Therapy, 20(3), pp. 199-212. (doi: 10.1007/s40291-016-0201-8) (PMID:27139908)
Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi: 10.1038/nature16965) (PMID:26909576)
Moran-Jones, K. et al. (2015) Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 6(42), pp. 44551-44562. (doi: 10.18632/oncotarget.6082) (PMID:26575166) (PMCID:PMC4792575)